GSK (GSK) Q3 Earnings and Revenues Beat Estimates

Company Performance - GSK reported quarterly earnings of $1.48 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and up from $1.27 per share a year ago, representing an earnings surprise of +17.46% [1] - The company posted revenues of $11.52 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.23%, compared to year-ago revenues of $10.42 billion [2] - Over the last four quarters, GSK has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - GSK shares have increased approximately 29.2% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.68 on revenues of $11.01 billion, and for the current fiscal year, it is $4.37 on revenues of $42.56 billion [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which GSK belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]